丨2026年3月2日星期一丨 NO.1正大天晴1类新药获批上市 国家药品监督管理局(NMPA)官网显示,正大天晴的1类新药罗伐昔替尼片(Rovadicitinib,TQ05105)在国内获批上市,适用于中危-2或高危的原发性骨髓纤维化(PMF)、真性红细胞增多症后骨髓纤维化(PPV-MF)或原发性血小板增多症后骨髓纤维化(PET-MF)成人患者的一线治疗,治疗疾病相关脾肿大或疾病相关症状。 ...
Source Link丨2026年3月2日星期一丨 NO.1正大天晴1类新药获批上市 国家药品监督管理局(NMPA)官网显示,正大天晴的1类新药罗伐昔替尼片(Rovadicitinib,TQ05105)在国内获批上市,适用于中危-2或高危的原发性骨髓纤维化(PMF)、真性红细胞增多症后骨髓纤维化(PPV-MF)或原发性血小板增多症后骨髓纤维化(PET-MF)成人患者的一线治疗,治疗疾病相关脾肿大或疾病相关症状。 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.